SCHEMBL10090752

SCHEMBL10090752

O=C1CC(c2ccccc2)c2cc3c(cc2N1)OCO3

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.76
SMN1; SMN2 Q16637 9/20 0.73
MAPT P10636 3/20 0.73
ALDH1A1 P00352 2/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
TP53 P04637 5/20 0.66
CYP1A2 P05177 1/20 0.65
CYP3A4 P08684 1/20 0.65
CYP2D6 P10635 1/20 0.65
CYP2C9 P11712 1/20 0.65
CYP2C19 P33261 1/20 0.65
THRB P10828 1/20 0.64
TSHR P16473 2/20 0.62
MEN1 O00255 1/20 0.62
MAPK1 P28482 1/20 0.62
KMT2A Q03164 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
ALOX15 P16050 1/20 0.60
RAB9A P51151 1/20 0.60
HTT P42858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10090742 0.92 TP53 (0.76) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL880284 0.86 TP53 (0.85) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL880292 0.86 LMNA (0.71) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL880439 0.86 LMNA (0.71) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL880309 0.86 LMNA (0.71) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL19286329 0.86 LMNA (0.71) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL880278 0.83 SMN1; SMN2 (0.73) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL21667414 0.83 SMN1; SMN2 (0.65) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL10280606 0.83 SMN1; SMN2 (0.65) LMNASMN1; SMN2MAPTALDH1A1L3MBTL1
SCHEMBL10280607 0.80 TSHR (0.87) LMNASMN1; SMN2MAPTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160166553-A1 ANTIMETASTATIC COMPOUNDS UNIV BRIGHAM YOUNG (US) 2016-06-16 US disclosed
US-20130158035-A1 ANTIMETASTATIC COMPOUNDS BRIGHAM YOUNG UNIVERSITY (US) 2013-06-20 US disclosed
WO-2012027392-A2 ANTIMETASTATIC COMPOUNDS BRIGHAM YOUNG UNIVERSITY (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158035-A1 ANTIMETASTATIC COMPOUNDS MET, HGFAC, HGF LMNA 3658/4885SMN1; SMN2 4322/4885MAPT 4206/4885
US-20160166553-A1 ANTIMETASTATIC COMPOUNDS MET, HGFAC, HGF LMNA 3658/4885SMN1; SMN2 4322/4885MAPT 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.